ZyVersa Therapeutics, Inc.
ZVSA
$0.18
-$0.02-11.21%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.43% | -13.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.94% | -4.69% | |||
| Operating Income | -2.94% | 4.69% | |||
| Income Before Tax | -834.17% | 2.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -795.65% | 2.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -795.65% | 2.02% | |||
| EBIT | -2.94% | 4.69% | |||
| EBITDA | -2.94% | 4.69% | |||
| EPS Basic | -457.07% | 36.77% | |||
| Normalized Basic EPS | 43.50% | 36.76% | |||
| EPS Diluted | -457.07% | 36.77% | |||
| Normalized Diluted EPS | 43.50% | 36.76% | |||
| Average Basic Shares Outstanding | 60.79% | 54.95% | |||
| Average Diluted Shares Outstanding | 60.79% | 54.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||